ArticleBrain sciences2020
Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study.
Article in Brain sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.Headache · 2026Trial
- UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine.Brain and behavior · 2026Article
- Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025.Journal of cannabis research · 2025Article
- Cannabinoids rescue migraine symptoms caused by central CGRP administration in mice.Cephalalgia : an international journal of headache · 2025Article
- Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks.Biomedicines · 2025Review
- Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice.Cephalalgia : an international journal of headache · 2025Article
- Interplay between cannabinoids and the neuroimmune system in migraine.The journal of headache and pain · 2024Review
- Characterizing Cannabis Use and Perceived Benefit in a Tertiary Headache Center Patient Sample.Neurology. Clinical practice · 2024Article
- The Exploration of Cannabis and Cannabinoid Therapies for Migraine.Current pain and headache reports · 2023Review
- Medical Cannabis: A Review from the American Society of Pain and Neuroscience.Journal of pain research · 2023Article
- Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.Behavioural neurology · 2023Review
- Review
- Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.Journal of clinical medicine · 2022Review
- Review
- Review
- Review
- Cannabis and Migraine: It's Complicated.Current pain and headache reports · 2021Review
- Medical Cannabis Use and Pain: An Experience Sampling Study.Frontiers in psychiatry · 2021Article
- Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior.Brain sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMedical cannabis (MC) treatment for migraine is practically emerging, although sufficient clinical data are not available for this indication. This cross-sectional questionnaire-based study aimed to investigate the associations between phytocannabinoid treatment and migraine frequency.
methodsParticipants were migraine patients licensed for MC treatment. Data included self-reported questionnaires and MC treatment features. Patients were retrospectively classified as responders vs. non-responders (≥50% vs. <50% decrease in monthly migraine attacks frequency following MC treatment initiation, respectively). Comparative statistics evaluated differences between these two subgroups.
resultsA total of 145 patients (97 females, 67%) with a median MC treatment duration of three years were analyzed. Compared to non-responders, responders (
conclusionsThese findings indicate that MC results in long-term reduction of migraine frequency in >60% of treated patients and is associated with less disability and lower antimigraine medication intake. They also point to the MC composition, which may be potentially efficacious in migraine patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.